Interesting interview - pretty overarching view of the Q3 revenue growth and sounds like it's sustainable.
Good update on Halucnex too - if the clinical trials continue on this trajectory it could be a gamechanger.
But the big takeaway was the question relating revenue growth to share price. Surely this level of sustained revenue growth translates into some uplift in the SP?
Interesting interview - pretty overarching view of the Q3...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ME1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $460.9K | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $41.65K | 16.96M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 80 | 55760188 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 7163212 | 6 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| ME1 (ASX) Chart |